by Genova Service Department

Since August this year, Genova Biotech and five leading Covid-19 new coronavirus vaccine and new drug enterprises in the world (Japan, the United States, Switzerland, India, etc.) have conducted technical and producted conditioning evaluation and cooperated negotiation on providing services such as amplification of Covid-19 new coronavirus vaccine production process, emergency production and international commercial production.

Based on the technology, production facilities, production capacity，comprehensive operation and management ability of Genova Biotech, Japan gene technology specialization company (listed on the East stock exchange, focusing on gene therapy and Covid-19 new coronavirus vaccine research and development) signed a letter of intent with Genova Biotech on November 4 for its global original and clinically leading gene Covid-19 new coronavirus vaccine technology development and contract production (CDMO) project (the cooperation cost is US $110 million). Genova Biotech provides CDMO services for gene vaccine technology improvement, process optimization, quality index establishment, enlarged production and emergency product reservation, including about US $15 million for Genova Biotech (Changzhou).

The order business expands the international new industry model of Genova Biotech, establishes the global industry leading position in the CDMO field of Covid-19 new coronavirus vaccine, and increases the new technical route of vaccine R & D and production in China.